Exporting Medical Gloves to the US: FDA Route and Test Items

Two misconceptions worth clearing first

To sell medical gloves in the United States, the mainstream route is a 510(k) premarket notification and a decision allowing the device to be marketed. It is not a matter of getting a number and shipping. Two misunderstandings come up often enough in client conversations that they belong at the top.

The first concerns FDA establishment registration and device listing. Both are annual administrative actions, and completing them only means FDA knows the facility exists and the product exists. It does not mean the product is allowed on the market. We have seen manufacturers send a screenshot of the registration from their agent to a customer as if it were a clearance, only to have the buyer's compliance team send it back. The rework is expensive.

The second concerns existing domestic reports. A type test report produced against GB 10213 or GB 7543 does not become 510(k) performance data by being translated into English. US review is about comparability with the predicate device on the way performance is characterised: whether the test method is the same, whether the parameter names line up, and whether the acceptance approach can be compared side by side. Many items in a national standard report do have a corresponding item and method on the US side, but the way the results are presented does not match, and the reviewer will pick those apart item by item during the substantial equivalence comparison.

Once those two are settled, the workload becomes easy to estimate: fix the classification, then the predicate, then work backwards to the test list.

Examination gloves and surgical gloves diverge at the classification step

These are two different standards domestically, and in the US they diverge even earlier: classification, product code, predicate pool and depth of testing are all different. Fixing which product you are before you start is the single most cost-effective decision in the project.

Only one ASTM number appears in that table, because nitrile examination gloves have a clearly applicable performance specification in ASTM D6319. The surgical glove line has its own material and performance specifications in the US, but for the specific ASTM designation and its currently effective version, rely on a search of the FDA recognised consensus standards database rather than on this article. Recognition status for consensus standards moves over time, and hard-coding a number into an article is a good way to get a schedule and a quotation built on the wrong basis.

A practical warning: do not push a product that should be filed as a surgical glove onto the examination glove line because the requirements look lighter. As soon as the labelling claims a surgical use, the predicate has to be a surgical glove, every test you saved has to be run after all, and the packaging and instructions you already printed have to be redone.

The gates to pass before marketing

Classification and product code. Medical gloves have a defined device classification and corresponding product codes in the US, and whether a 510(k) is required or an exemption applies is determined by the current record in the FDA classification database. We suggest your regulatory colleague query the database directly rather than borrowing a conclusion from a competitor, whose product code may not match your intended use.

The 510(k) submission. 510(k)s are now required to be submitted using the electronic submission template, which means performance data, biological evaluation, sterilisation and packaging where applicable, and draft labelling all have to land in the right fields. The technical difficulty with a product like gloves is not that any single test is hard; it is completeness. One missing performance comparison generates a deficiency letter, and the calendar cost of one deficiency round is often higher than the cost of the testing itself.

Registration and listing, US agent, and labelling. A foreign manufacturer has to designate a U.S. Agent, complete establishment registration and device listing, and maintain both annually. Whether UDI and GUDID data submission applies, and to what extent, depends on the device classification and any exemptions, and has to be checked item by item against current FDA requirements.

Quality system. FDA can inspect a foreign facility, and quality system documentation and production records have to survive a traceability exercise. Gloves are a continuous high-volume product, and lot traceability, retained samples and release records are the areas most likely to be exposed during an inspection.

Building the test list

It becomes much clearer if you split glove testing into three blocks: barrier and physical performance, chemistry and residues, and biological evaluation. The table below assigns items by product type. For the specific test methods, sampling levels and acceptance limits, the currently effective version of the standard text governs.

A few details you only learn by running these projects.

Physical performance before and after ageing is a pair of datasets, not one. Plenty of submitters send only the as-received condition, discover when the report comes back that the post-ageing comparison is missing, and have to schedule samples again. The subtler trap is in sampling: where on the glove the tensile specimens are cut from and at which locations thickness is measured are specified in the standard, and moulded thickness naturally varies across a glove. Take specimens from different locations within the same lot and the numbers will differ, which is easy to misread as process instability during a side-by-side comparison. Reconciling the sampling and measurement locations against the standard text before testing is far cheaper than explaining the data afterwards.

Barrier integrity is a lot-based sampling item. Sampling level and acceptance quality limit follow the standard, and the currently effective version of the standard text governs the numbers. In practice we suggest reserving samples for the larger sample size you might need, plus an extra set from the same lot. If a retest is called for, same-lot samples are much faster than producing new ones. It is also worth remembering that this item assesses the quality level of the lot, not whether an individual glove passes, so pulling a handful of gloves and having them checked tells you nothing reliable about the lot conclusion.

Dimension and sizing sampling is driven by the size range. The more size increments you have, the more samples you need. Some manufacturers submit only the middle size to save samples, then find the largest and smallest sizes have no data and the performance comparison table cannot be completed. Fix the list of sizes you intend to market in the US before the project starts and plan samples by size; adding them mid-project costs more.

Biological evaluation, conclusion first. Gloves are surface-contacting devices in contact with intact skin, with relatively short contact duration. In practice the usual combination is cytotoxicity (ISO 10993-5) and sensitisation (ISO 10993-10), with irritation-type endpoints included based on material, process and residues. Products containing natural rubber latex additionally require attention to protein-related sensitisation risk. The full logic of selecting endpoints by contact type and contact duration is outside the scope of this article; if you want to work through it systematically, the evaluation pathway is described under biocompatibility testing. Which parts of the ISO 10993 series a report cites and which version it follows should always be checked against the currently effective version rather than copied from an old template.

Viral penetration and chemotherapy drug permeation are claim-driven. If you do not make that kind of protective claim on the label, you do not need the testing. If you do make it, the data has to support it, and the wording of the claim has to correspond strictly to what the testing covered. This is the item a sales colleague most often adds to marketing material on impulse, leaving the regulatory team to run the tests after the fact.

Powder-free and natural rubber latex: two easy compliance trips

Under FDA's banned devices provisions, powdered patient examination gloves, powdered surgical gloves, and absorbable powder for lubricating surgical gloves are banned devices. In practical terms, medical gloves exported to the US have to be designed powder-free from the start, with residual powder data ready to support the powder-free claim. This is a precondition with no room for negotiation, not an option.

Note that powder-free does not mean no powder ever appears on the line. Process residues from demoulding and cross-contamination from shared lines both show up in residual powder data. If the same line still runs powdered product for other markets, your line-clearance and validation records need to explain that clearly, or there is no way to account for an anomalous result.

Natural rubber latex carries a separate line: when a product contains natural rubber latex, the labelling has to carry the corresponding statement required by FDA, and must not use wording that could lead users to misjudge the allergy risk. The exact wording follows current FDA requirements, and we suggest having a regulatory consultant review the labelling before it is finalised. Nitrile avoids this issue, which is part of why export products have been shifting towards nitrile in recent years; for nitrile examination gloves the performance specification to work to is ASTM D6319.

What is specific to predicate selection for gloves

The general methodology of predicate comparison, whether the predicate is legally marketed, whether the intended use matches, and whether differences in technical characteristics raise new questions of safety and effectiveness, is not covered here. What follows is the three hurdles specific to this category.

Powder status cannot be explained away as an ordinary difference. Powdered products are banned, so if the predicate you picked is an older powdered model, the basis for comparison does not exist and you need to find a powder-free predicate instead.

Switching material from natural rubber latex to nitrile is a substantive change affecting physical performance and biological evaluation at the same time. It cannot be waved through on the grounds that both are gloves; the compound system, curing agents and extractables profile all change with it.

Examination gloves and surgical gloves are separate lines, and the predicate has to come from the same line. Using an examination glove predicate to support a claim involving surgical use is one of the more typical sources of rework we have seen.

What to prepare before submitting samples

Across the glove projects we have run, how complete the up-front information is directly determines how fast the report comes out. We suggest having the following ready:

• Basic product information: material, compound category, whether it contains natural rubber latex, powder-free or powdered, sterile status and sterilisation method.
• Intended claims: intended use, use environment, and any protective claims. Claims determine the test list, and this matters more than anything else on the list.
• Size and specification list: which sizes and which thickness grades need to be covered, and whether there are differences between production lines.
• Statement of sample condition: whether the submitted samples are in final form, meaning final formulation, final process, final packaging and already sterilised. Physical performance data generated on unsterilised samples cannot directly support conclusions about the sterilised product.
• Line and mould information: where several lines or several sets of formers produce the same model, describe the differences and which line's samples are intended to represent the rest. Missing this means additional testing when you expand production later.
• Lot planning: different items have different lot requirements. Stability and sterilisation-related items typically require coverage of multiple lots, and scheduling production in advance saves time compared with adding lots afterwards.
• Sample quantity and retained samples: reserve for the largest sample size you might need, and keep spare samples from the same lot.
• Change records: whether the latex or nitrile compound supplier has changed recently, and whether the formulation or curing process has been adjusted. Change points directly determine whether historical data can still be used.
• Existing reports: domestic type test reports, EN 455 series reports and previous biological evaluation material. Lay out what can be reused before deciding anything.

Sterile models also need sterilisation validation and packaging validation scheduled alongside, and both are tied to shelf life. However long the shelf life you intend to claim, the stability and accelerated ageing protocol has to be designed for that duration; changing the claim mid-way means starting over.

How much of your existing GB and EN 455 work can be reused

The honest answer: the thinking and the samples can be reused, the reports often cannot be used as they stand.

For dimensions, physical performance and barrier integrity, GB 10213 and GB 7543 and the EN 455 series examine the same engineering properties as the US route, so the product-level preparation carries over. The formulation and process optimisation you did for the EU route still holds for the US route. The differences land in four places: specimen geometry and sampling location are not specified identically; the ageing conditions and the way results are assessed are expressed differently; sampling plans and acceptance criteria are framed differently; and the data presentation differs, with some requiring summary statistics and others requiring values glove by glove. None of these differences is large on its own, but together they are enough to leave an existing report unable to line up in the comparison table, which is why reports generally have to be reissued or supplemented for the US route.

Biocompatibility reuses better. If the previous evaluation was carried out systematically under the ISO 10993 series and the material, manufacturing process and sterilisation method have not changed, the evaluation material can usually continue to serve as part of the overall evaluation. Change the supplier, the formulation or the sterilisation method and the impact of that change has to be reassessed. Do not cut this corner: carrying old data forward after a change is one of the more common reasons for a deficiency letter.

A practical suggestion: if the product is planned for both the EU and the US, merge the two test lists into a single schedule at the project planning stage, produce samples once and stagger the testing. That saves a meaningful amount of time and sample cost compared with finishing one route and then starting the other. Put ageing and stability at the front of the schedule, because those lead times are essentially incompressible and everything else can be slotted in around them.

About SUNGO Lab

SUNGO Lab is a third-party medical device testing organisation accredited by CNAS, CMA and IAS (USA), with laboratories in Shanghai and Hefei. To be explicit about what that means: an accreditation mark only demonstrates that the laboratory has the corresponding technical competence within its accredited scope, and does not constitute a commitment as to the outcome of market access in any target market. Whether a report is accepted, and whether a product is allowed on the market, depends on the overall quality of the submission and the conclusions of the reviewing authority.

For medical gloves we can carry out physical performance and barrier integrity testing, biological evaluation, sterilisation and packaging validation, and stability and shelf life studies, and we can align report formats and documentation with what an export submission requires. What we provide is the testing and validation piece; regulatory strategy and submission handling are better led by your own regulatory team or a specialist consultant, which is also the most efficient division of labour.

If you are planning an export route for medical gloves and are unsure which tests apply, how to plan samples, or how much of your existing reporting can be used, send us the product information and your intended claims. Call +86 132 4819 8029 or request a quote for a test plan and lead time estimate broken down by product type.